Full-Time
Confirmed live in the last 24 hours
$110.6k - $138.2k/yr
Senior
Tampa, FL, USA
This position can be performed remotely but also has a physical office in Tampa, FL.
Company Size
201-500
Company Stage
IPO
Headquarters
Alachua, Florida
Founded
2002
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Parental Leave
Paid Caregiver Leave
Basic Life Insurance
Supplemental Life Insurance
Disability Insurance
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations.
Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair.
Axogen names ex-abbott exec Michael Dale as CEO.
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S
ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024.“Today’s milestone represents a significant step in our regulatory transition of Avance Nerve Graft to a biologic,” said Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “I am grateful to our Axogen team and their diligence as we work towards completing the rolling BLA submission process.”The initial submission to the U.S. FDA includes the complete non-clinical data package for the BLA